Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 50 of 86 entries
View as:

Dose Escalation Study of the Pharmacodynamics, Pharmacokinetics, Safety, and Immunogenicity of BCD-132 in Patients With Relapsing-Remitting Multiple Sclerosis

Phase: N/A Priority: Normal
NCT ID: NCT03551275 Org: User:
Start: 02/22/18 End: 03/28/19 Due: 03/28/20

Study of BCD-115 in Women With ER(+) HER2(-) Local Advanced and Metastatic Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03065010 Org: User:
Start: 11/30/16 End: 03/31/18 Due: 03/31/19

Study of the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of BCD-180 in Patients With Axial Spondyloarthritis (LEVENTA)

Phase: N/A Priority: Normal
NCT ID: NCT06333210 Org: User:
Start: 12/25/23 End: 02/29/28 Due: 02/28/29

Comparative Study of the Efficacy and Safety of BCD-131 and Mircera in Treatment of Anemia in CKD Patients on Dialysis

Phase: N/A Priority: Normal
NCT ID: NCT03519243 Org: User:
Start: 10/24/17 End: 12/10/18 Due: 12/10/19

Pharmacokinetics and Pharmacodynamics Study of BCD-033 Compared to Rebif® in Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT01766024 Org: User:
Start: 02/28/13 End: 06/30/13 Due: 06/30/14

Study of the Efficacy and Safety of Empegfilgrastim for Neutropenia Prophylaxis in Breast Cancer Patients

Phase: N/A Priority: Normal
NCT ID: NCT02104830 Org: User:
Start: 09/30/13 End: 10/31/14 Due: 10/31/15

First-in-human Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Various Doses of BCD-121 in Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT03103451 Org: User:
Start: 11/30/16 End: 05/31/17 Due: 05/31/18

Clinical Study of the Efficacy and Safety of BCD-178 and Perjeta® as Neoadjuvant Therapy of HER2-Positive Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05802225 Org: User:
Start: 01/30/23 End: 01/31/26 Due: 01/31/27

The Study of PK, PD, Safety of Multiple Intravenous Injections of BCD-066 and Aranesp in Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT03693950 Org: User:
Start: 03/28/17 End: 07/03/17 Due: 07/03/18

An Extension Clinical Study of the Efficacy and Safety of BCD-132 in Patients With Multiple Sclerosis Who Previously Received Therapy in Clinical Studies of JSC BIOCAD

Phase: N/A Priority: Normal
NCT ID: NCT06987851 Org: User:
Start: 03/22/22 End: 05/16/24 Due: 05/16/25

Study of the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of BCD-180 in Patients With Axial Spondyloarthritis

Phase: N/A Priority: Normal
NCT ID: NCT05445076 Org: User:
Start: 04/19/22 End: 06/30/27 Due: 06/30/28

Study of the Safety, Pharmacodynamics and Efficacy of ANB-002 in Patients With Hemophilia B (SAFRAN)

Phase: N/A Priority: Normal
NCT ID: NCT06120582 Org: User:
Start: 05/02/23 End: 11/30/29 Due: 11/30/30

Open Label Study of Tolerability, Pharmacokinetics and Pharmacodynamics of BCD-054 (Pegylated Interferon Beta-1a), IM and SC, Compared to Rebif® and Avonex® in Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT02359877 Org: User:
Start: 07/31/14 End: 12/31/15 Due: 12/31/16

International Clinical Trial to Evaluate Efficacy and Safety of Multiple Subcutaneous Injections of BCD-085 in Various Doses in Patients With Moderate to Severe Plaque Psoriasis

Phase: N/A Priority: Normal
NCT ID: NCT02762994 Org: User:
Start: 06/30/16 End: 05/31/17 Due: 05/31/18

The BCD-089 (aIL6R) in Patients With Active Rheumatoid Arthritis

Phase: N/A Priority: Normal
NCT ID: NCT03455842 Org: User:
Start: 02/01/18 End: 10/22/19 Due: 10/22/20

Evaluation the Pharmacokinetics, Safety, Tolerability of BCD-021 in Patients With Neovascular Age-related Macular Degeneration

Phase: N/A Priority: Normal
NCT ID: NCT02450981 Org: User:
Start: - End: - Due: -

A Study of BCD-135 in Patients With Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT03464032 Org: User:
Start: 10/31/17 End: 10/31/18 Due: 10/31/19

A Trial of the Safety and Efficacy of Single-Dose Administration of ANB-010 in Subjects With Hemophilia A

Phase: N/A Priority: Normal
NCT ID: NCT06185335 Org: User:
Start: 07/26/23 End: 06/30/33 Due: 06/30/34

Study of Pharmacokinetics, Pharmacodynamics, Safety of BCD-131 Compared to Mircera and Aranesp in Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT02731469 Org: User:
Start: 06/15/16 End: 03/31/17 Due: 03/31/18

A Clinical Study of the Pharmacokinetics and Safety of BCD-263 and Opdivo® as Monotherapy in Subjects With Advanced Melanoma of the Skin

Phase: N/A Priority: Normal
NCT ID: NCT06112808 Org: User:
Start: 05/29/23 End: 01/31/27 Due: 01/31/28

Safety and Efficacy Study of BCD-020 in Therapy of Indolent Non-Hodgkin's Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT01701232 Org: User:
Start: 09/30/11 End: 01/31/17 Due: 01/31/18

Study of Efficacy and Safety of BCD-217 (Anti-CTLA-4 and Anti-PD-1) Followed By BCD-100 (Anti-PD-1) Versus BCD-100 Monotherapy as First-Line Treatment in Patients With Unresectable or Metastatic Melanoma

Phase: N/A Priority: Normal
NCT ID: NCT03913923 Org: User:
Start: 07/01/19 End: 12/31/23 Due: 12/31/24

Prolgolimab 250 mg Q3W in Patients With Unresectable or Metastatic Melanoma

Phase: N/A Priority: Normal
NCT ID: NCT05783882 Org: User:
Start: 02/01/22 End: 06/30/23 Due: 06/30/24

An Open-Label, Comparative Study of the Efficacy, Safety and Pharmacodynamics of Single Dose of ANB-002 in Patients With Hemophilia B

Phase: N/A Priority: Normal
NCT ID: NCT06700096 Org: User:
Start: 11/07/24 End: 03/31/32 Due: 03/31/33

Clinical Study of Divozilimab in Patients With Systemic Scleroderma

Phase: N/A Priority: Normal
NCT ID: NCT05726630 Org: User:
Start: 12/26/22 End: 02/01/27 Due: 02/01/28